Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 7/20 | 0.41 |
| ▸ | EGFR | P00533 | 6/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111262 | 0.89 | ALDH1A1 (0.42) | PDGFRBEGFRKDRHDAC8HDAC6 | |
| SCHEMBL2259064 | 0.81 | PDGFRB (0.41) | PDGFRBEGFRKDRHDAC8HDAC6 | |
| SCHEMBL14410306 | 0.75 | KDR (0.61) | PDGFRBEGFRKDRHDAC8HDAC6 | |
| SCHEMBL3109889 | 0.73 | KDR (0.61) | PDGFRBEGFRKDRPDGFRA | |
| SCHEMBL14270084 | 0.71 | EGFR (0.62) | PDGFRBEGFRKDRHDAC8HDAC6 | |
| SCHEMBL2263021 | 0.71 | EGFR (0.55) | PDGFRBEGFRKDRHDAC8HDAC6 | |
| SCHEMBL3108338 | 0.70 | KDR (0.68) | PDGFRBEGFRKDRHDAC8HDAC6 | |
| SCHEMBL2256621 | 0.69 | ABCG2 (0.51) | PDGFRBEGFRKDRCYP1A2CYP3A4 | |
| SCHEMBL3107580 | 0.69 | EGFR (0.47) | PDGFRBEGFRKDRHDAC8HDAC6 | |
| SCHEMBL2257287 | 0.66 | PDGFRB (0.70) | PDGFRBEGFRKDRHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | PDGFRB 2620/4885EGFR 2915/4885KDR 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.